[go: up one dir, main page]

WO2000027842A1 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
WO2000027842A1
WO2000027842A1 PCT/SE1999/001988 SE9901988W WO0027842A1 WO 2000027842 A1 WO2000027842 A1 WO 2000027842A1 SE 9901988 W SE9901988 W SE 9901988W WO 0027842 A1 WO0027842 A1 WO 0027842A1
Authority
WO
WIPO (PCT)
Prior art keywords
methoxy
pyridinamine
piperidinyl
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE1999/001988
Other languages
French (fr)
Inventor
Anthony Cook
Peter Hamley
Alan Tinker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Priority to AU14345/00A priority Critical patent/AU1434500A/en
Priority to JP2000581020A priority patent/JP2002529463A/en
Priority to EP99971807A priority patent/EP1124821A1/en
Publication of WO2000027842A1 publication Critical patent/WO2000027842A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the compounds of the present invention are clearly distinguished from those of the prior art by virtue of the nature of the particular substituents attached to the 2-aminopyridine ring.
  • R represents hydr ⁇ gen or one or more substituents selected independently from Cl to 6
  • R independently represent hydrogen or Cl to 4 alkyl; 2 4 or R and R are joined together and represent -[CH2] m -;
  • Y represents hydrogen or Cl to 4 alkyl
  • the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers have the advantage that they are inhibitors of the enzyme nitric oxide synthase (NOS).
  • NOS nitric oxide synthase
  • the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers have the advantage that they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase (iNOS).
  • a more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.
  • a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
  • a method of treating, or reducing the risk of, inflammation, inflammatory disease and inflammatory related disorders in a person suffering from or at risk of, said disease or condition comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof in combination with a COX-2 inhibitor.
  • Q in formula (I) represents hydrogen, halogen or cyano.
  • Particular compounds of the invention include:
  • Cl to 6 alkyl denotes a straight or branched chain alkyl group having from 1 to 6 carbon atoms or a cyclic alkyl group having from 3 to 6 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, cyclopentyl and cyclohexyl.
  • Cl to 6 alkoxy denotes a straight or branched chain alkoxy group having from 1 to 6 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy and t-butoxy.
  • alkylthio are to be interpreted similarly.
  • Examples of a five membered aromatic heterocyclic ring containing one to three heteroatoms selected independently from O, S or N, or a six membered aromatic azacyclic ring containing one or two nitrogen atoms include furan, thiophene, pyrrole, thiazole, oxazole, imidazole, triazole, thiadiazole, pyridine, pyrimidine, pyrazine and pyridazine.
  • bicyclic aromatic heterocyclic ring system containing one to three heteroatoms independently selected from O, S or N examples include quinoline, isoquinoline, benzofuran, benzothiophene, benzothiazole, indole and benzotriazole.
  • R , R , R , R , X, Y and Z are as defined above with an acyl derivative of formula (HI)
  • Q and A are as defined above and L represents a leaving group
  • R , R , R ' A, Q, X, Y and Z are as defined above;
  • R , R , R , A, Q, X, Y and Z are as defined above;
  • the present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts.
  • Suitable salts include those formed with both organic and inorganic acids.
  • Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question.
  • preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.
  • the preparation of compounds of formula (II) may be achieved by reaction of a compound of formula (IV) with a compound of formula (VET)
  • the preparation of compounds of formula (II) may be achieved by reaction of a compound of formula (VI) with a compound of formula (IX) using the methodology of process (c) above.
  • Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.
  • the compounds of formula (I) may exist in alternative tautomeric forms.
  • Compounds of formula (I) are provided in another tautomeric form or as a mixture thereof.
  • the compounds of formula (I), and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers, are useful because they possess pharmacological activity in animals.
  • the compounds are active as inhibitors of the enzyme nitric oxide synthase. More particularly, they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase and as such are predicted to be useful in therapy, for example, as anti-inflammatory agents. They may also have utility as inhibitors of the neuronal isoform of the enzyme nitric oxide synthase.
  • the compounds and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers are indicated for use in the treatment or prophylaxis of diseases or conditions in which synthesis or oversynthesis of nitric oxide synthase forms a contributory part.
  • the compounds are indicated for use in the treatment of inflammatory conditions in mammals including man.
  • Conditions that may be specifically mentioned are: osteoarthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, inflamed joints; eczema, psoriasis, dermatitis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including uveitis and conjunctivitis; lung disorders in which inflammation is involved, for example, asthma, bronchitis, chronic obstructive pulmonary disease, pigeon fancier's disease, farmer's lung, acute respiratory distress syndrome; bacteraemia, endotoxaemia (septic shock), aphthous ulcers, gingivitis, pyresis, pain, meningitis and pancreatitis; conditions of the gastrointestinal tract including inflammatory bowel disease, Crohn's disease, atrophic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileit
  • the compounds will also be useful in the treatment and alleviation of acute pain or persistent inflammatory pain or neuropathic pain or pain of a central origin.
  • the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers may also be useful in the treatment or prophylaxis of diseases or conditions in addition to those mentioned above.
  • the compounds may be useful in the treatment of atherosclerosis, glaucoma, cystic fibrosis, hypotension associated with septic and/or toxic shock, in the treatment of dysfunction of the immune system, as an adjuvant to short-term immunosuppression in organ transplant therapy, in the control of onset of diabetes, in the maintenance of pancreatic function in diabetes, in the treatment of vascular complications associated with diabetes and in cotherapy with cytokines, for example TNF or interleukins.
  • cytokines for example TNF or interleukins.
  • the compounds of formula (I) may also be useful in the treatment of hypoxia, for example in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as ischaemia, hypoxia, hypoglycaemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia, for example pre-senile dementia, Alzheimer's disease and ADDS-related dementia, Sydenham's chorea, Parkinson's disease, Tourette's Syndrome, Huntington's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Korsakoffs disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, pain, autism, seasonal affective disorder, jet-lag, depression or other symptoms associated with Premenstrual Syndrome (PMS), anxiety and septic shock.
  • PMS Premenstrual Syndrome
  • Compounds of formula (I) may also be expected to show activity in the prevention and reversal of tolerance to opiates and diazepines, treatment of drug addiction, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of gastrointestinal motility disorders, cancer and in the induction of labour.
  • Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
  • Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
  • the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.
  • the compounds of formula (I), and pharmaceutically acceptable derivatives thereof may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, intravenous, topical or other parenteral routes.
  • enteral including oral, sublingual or rectal
  • intranasal intranasal
  • intravenous topical or other parenteral routes.
  • Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
  • the pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
  • the compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may also be advantageously used in combination with a COX-2 inhibitor.
  • COX-2 inhibitors are Celecoxib and MK-966.
  • the NOS inhibitor and the COX-2 inhibitor may either be formulated together within the same pharmaceutical composition for administration in a single dosage unit, or each component may be individually formulated such that separate dosages may be administered either simultaneously or sequentially.
  • Methyl phosphonium bromide (7.1 g, 0.02 mol) was suspended in tetrahydrofuran (75 ml) and 2M butyl lithium (10 ml in hexane, 0.02 mol) added at 0 °C. After 1 h at room temperature the solution was added dropwise over 30 min. to a solution of l-(4-chlorobenzoyl)-4-piperidone (2.38 g, 0.01 mol) in tetrahydrofuran (75 ml). After 16 h, water was added, followed by extraction with ether three times. The extracts were combined, dried over magnesium sulphate and evaporated. The residue was purified by flash column chromatography eluting with 30% ethyl acetate in hexane to yield the title compound as an oil. MS (+EI) m /z 236/238 (M + ).
  • N-ri-(3-FuranylcarbonylV4-piperidinyll-4-methyl-2-pyridinamine A mixture of 4-methyl-N-(4-piperidinyl)-2-pyridinamine (0.19 g, 1 mmol) (Intermediate B), 3-furancarboxylic acid (0.12 g, 1.1 mmol), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (0.7 g, 1.5 mmol) and Hunig's base (0.52 ml, 3 mmol) was stirred in dichloromethane for 20 h. The solution was diluted with water, separated and the organic layer dried (magnesium sulphate) and evaporated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

There are provided novel compounds of formula (I) wherein R?1, R2, R3, R4, R5¿, A, Q, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and tautomers thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.

Description

COMPOUNDS
Field of the Invention
The present invention relates to novel 2-aminopyridine derivatives, processes for their preparation, compositions containing them and their use in therapy.
Background of the Invention
Nitric oxide is produced in mammalian cells from L-arginine by the action of specific nitric oxide synthases (NOSs). These enzymes fall into two distinct classes - constitutive NOS (cNOS) and inducible NOS (iNOS). At the present time, two constitutive NOSs and one inducible NOS have been identified. Of the constitutive NOSs, an endothelial enzyme (ecNOS) is involved with smooth muscle relaxation and the regulation of blood pressure and blood flow, whereas the neuronal enzyme (ncNOS) serves as a neurotransmitter and appears to be involved in the regulation of various biological functions such as cerebral ischaemia. Inducible NOS has been particularly implicated in the pathogenesis of inflammatory diseases. Regulation of these enzymes should therefore offer considerable potential in the treatment of a wide variety of disease states (J. E. Macdonald, Ann. Rep. Med. Chem., 1996, 31, 221 - 230).
Considerable effort has been expended in efforts to identify compounds that act as specific inhibitors of one or more isoforms of the enzyme nitric oxide synthase. The use of such compounds in therapy has also been widely claimed. One group of these compounds incorporates within their structures a 2-aminopyridine moiety. Thus, WO 96/18616 and WO 96/18617 (both to Merck & Co., Inc.) describe substituted 2-aminopyridines of general formula:
Figure imgf000003_0001
and WO 97/36871 (Pfizer Inc.) describes 6-phenyl-2-aminopyridines of general formula:
Figure imgf000004_0001
The compounds of the present invention are clearly distinguished from those of the prior art by virtue of the nature of the particular substituents attached to the 2-aminopyridine ring.
Disclosure of the invention According to the present invention, there is provided a compound of formula (I)
Figure imgf000004_0002
wherein:
6„7_ X represents -[CR R ]n-;
R represents hydrøgen or one or more substituents selected independently from Cl to 6
8 9 alkyl, Cl to 6 alkoxy, halogen and NR R ;
R ,
Figure imgf000004_0003
independently represent hydrogen or Cl to 4 alkyl; 2 4 or R and R are joined together and represent -[CH2]m-;
Y represents hydrogen or Cl to 4 alkyl;
2 or R and Y are joined together and represent -[CH2_p-
4 or R and Y are joined together and represent -[CH2Jp-;
or Y is joined to the ortho position of ring A and represents -[CH2_r
Z represents a bond or -CH2-;
Q represents hydrogen or one or more substituents selected independently from Cl to 6 alkyl, Cl to 6 alkoxy, Cl to 6 alkylthio, halogen, cyano, trifluoromethyl, trifluoromethoxy, hydroxy, nitro, methanesulphonyl, sulphamoyl, benzyloxy, -NR R , -CO2R ,
11 12 -CONR R , a five membered aromatic heterocyclic ring containing one to three heteroatoms independently selected from O, S or N, a six membered aromatic azacyclic ring containing one or two nitrogen atoms, or phenyl, said phenyl being optionally further substituted by Cl to 6 alkyl;
R , R and R independently represent hydrogen or Cl to 4 alkyl;
A represents phenyl, naphthyl, a five membered aromatic heterocyclic ring containing one to three heteroatoms independently selected from O, S or N, a six membered aromatic azacyclic ring containing one or two nitrogen atoms, or a bicycfic aromatic heterocyclic ring system containing one to three heteroatoms independently selected from O, S or N;
m represents an integer 0 to 5; n represents an integer 0 to 3;
p represents an integer 0 to 4;
r represents an integer 0 to 3;
or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
The compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers have the advantage that they are inhibitors of the enzyme nitric oxide synthase (NOS). In particular, the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers have the advantage that they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase (iNOS).
The invention further provides a process for the preparation of compounds of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
According to the invention there is also provided a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof, for use as a medicament.
Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.
A more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.
According to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
More particularly, there is also provided a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
The compounds of the present invention may also be used advantageously in combination with a second pharmaceutically active substance, particularly in combination with a selective inhibitor of the inducible isoform of cyclooxygenase (COX-2). Thus, in a further aspect of the invention there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof, in combination with a COX-2 inhibitor for the treatment of inflammation, inflammatory disease and inflammatory related disorders. And there is also provided a method of treating, or reducing the risk of, inflammation, inflammatory disease and inflammatory related disorders in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof in combination with a COX-2 inhibitor.
Preferably, A in formula (I) represents a phenyl or pyridyl ring.
Preferably, Q in formula (I) represents hydrogen, halogen or cyano.
Preferably, R in formula (I) represents Cl to 6 alkyl or Cl to 6 alkoxy. More preferably, R in formula (I) represents methyl or methoxy.
Preferably, n in formula (I) represents 0 or 1. 2 In another preferred embodiment, R and Y in formula (I) are joined together and represent
2 -[CH2.2- and Z represents a bond and n = 1, such that R and Y together with the atoms to which they are attached represent a piperidinyl ring.
Particular compounds of the invention include:
N-[l-(3-furanylcarbonyl)-4-piperidinyl]-4-methyl-2-pyridinamine;
N-[ 1 -(4-cyanobenzoyl)-4-piperidinyl]-4-methyl-2-pyridinamine;
4-[[3-[(4-methoxy-2-pyridinyl)amino]-l-pyrrolidinyl]carbonyl]benzonitrile;
4-[[4-[(4-methoxy-2-pyridinyl)amino]-l-piperidinyl]carbonyl]benzonitrile; N-[ 1 -(4-bromobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[l-(4-chlorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-(2-thienylcarbonyl)-4-piperidinyl]-2-pyridinamine;
N- [ 1 - [(5-chloro-2-thienyl)carbonyl ] -4-piperidinyl] -4-methoxy-2-pyridinamine ;
4-[[4-[(4-methoxy-2-pyridinyl)amino]-l-piperidinyl]carbonyl]benzenesulphonamide; N-[ 1 -[(6-chloro-3-pyridinyl)carbonyl]-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-(2-pyrazinecarbonyl)-4-piperidinyl]-2-pyridinamine;
N-[l-(3,4-dichlorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-(3-thienylcarbonyl)-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-(4-methoxybenzoyl)-4-piperidinyl]-2-pyridinamine; N-[ 1 - { (5-bromo-2-thienyl)carbonyl } -4-piperidinyl] -4-methoxy-2-pyridinamine;
4-methoxy-N-[l-{(2-(4-pyridinyl)-4-thiazolyl)carbonyl}-4-piperidinyl]-2-pyridinamine;
N- [ 1 -(3 ,5-dibromobenzoyl)-4-piperidiny 1] -4-methoxy-2-pyridinamine ;
N-[l-(4-chloro-3-iodobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[l-(3-isoqunolinylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine; 4-methoxy-N-[ 1 -(6-quinoIinylcarbonyl)-4-piperidinyl]-2-pyridinamine;
N-[l-(3,5-difluorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[ 1 -[(5-methyl- 1-phenyl- lH-pyrazol-4-yl)carbonyl]-4-piperidinyl]-2- pyridinamine;
N- [ 1 - [4-(dimethylamino)benzoyl] -4-piperidinyl] -4-methoxy-2-py ridinamine; 4-methoxy-N-[ 1 -(3-quinolinylcarbonyl)-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-[(6-methyl-3-pyridinyl)carbonyl]-4-piperidinyl]-2-pyridinamine; 4-methoxy-N-[l-[4-(l _'-pyrrol-l-yl)benzoyl]-4-piperidinyl]-2-pyridinamine;
N-[ 1 -(4-iodobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[l-(l-benzothiophen-2-ylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[ 1 -[(4'-ethyl[ 1 , -biphenyl]-4-yl)carbonyl]-4-piperidinyl]-4-methoxy-2-pyridinamine; N-[l-(l_t_'-l,2,3-benzotriazol-5-ylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[ 1 -[4-( 1 -methylethyl)benzoyl]-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-(l,2,3-thiadiazol-4-ylcarbonyl)-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-(3-pyridinylcarbonyl)-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-(2-pyridinylcarbonyl)-4-piperidinyl]-2-pyridinamine; N-[l-(3-isoxazolylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-[(5-methyl-2-pyrazinyl)carbonyl]-4-piperidinyl]-2-pyridinamine;
N-[l-[4-(aminomethyl)benzoyl]-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-(4-pyridinylcarbonyl)-4-piperidinyl]-2-pyridinamine;
N-[l-(3-amino-4-chlorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine; N-[l-(4-cyanobenzoyl)-4-piperidinyl]-4-chloro-2-pyridinamine;
4-cyano-N-[3-[(4-methyl-2-pyridinyl)amino]propyl]benzamide;
4-cyano-N-[3-[(4-methoxy-2-pyridinyl)amino]propyl]benzamide;
N-[l-(4-chlorobenzoyl)-4-methyl-4-piperidinyl]-4-methoxy-2-pyridinamine; and pharmaceutically acceptable salts, enantiomers, racemates or tautomers thereof.
Unless otherwise indicated, the term "Cl to 6 alkyl " referred to herein denotes a straight or branched chain alkyl group having from 1 to 6 carbon atoms or a cyclic alkyl group having from 3 to 6 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, cyclopentyl and cyclohexyl.
Unless otherwise indicated, the term "Cl to 6 alkoxy " referred to herein denotes a straight or branched chain alkoxy group having from 1 to 6 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy and t-butoxy.
Other groups, for example, alkylthio, are to be interpreted similarly. Examples of a five membered aromatic heterocyclic ring containing one to three heteroatoms selected independently from O, S or N, or a six membered aromatic azacyclic ring containing one or two nitrogen atoms include furan, thiophene, pyrrole, thiazole, oxazole, imidazole, triazole, thiadiazole, pyridine, pyrimidine, pyrazine and pyridazine.
Examples of a bicyclic aromatic heterocyclic ring system containing one to three heteroatoms independently selected from O, S or N include quinoline, isoquinoline, benzofuran, benzothiophene, benzothiazole, indole and benzotriazole.
According to the invention, we further provide a process for the preparation of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof which comprises: (a) preparing a compound of formula (I) by reaction of a compound of formula (H)
Figure imgf000010_0001
wherein
1 2 3 4 5 R , R , R , R , R , X, Y and Z are as defined above with an acyl derivative of formula (HI)
Figure imgf000010_0002
wherein
Q and A are as defined above and L represents a leaving group;
or (b) preparing a compound of formula (I) by reaction of a compound of formula (IV)
Figure imgf000011_0001
wherein R is as defined above with a compound of formula (V)
Figure imgf000011_0002
2 4 5 wherein R , R , R ' A, Q, X, Y and Z are as defined above;
or (c) preparing a compound of formula (I) by reaction of a compound of formula (VI)
Figure imgf000011_0003
.1 . wherein R is as defined above with a compound of formula (VII)
Figure imgf000011_0004
2 3 4 5 wherein R , R , R , R , A, Q, X, Y and Z are as defined above;
and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof, or vice versa, and where desired converting the resultant compound of formula (I) into an optical isomer thereof. In process (a) above, the reaction will take place on stirring a mixture of the reactants in a suitable organic solvent at a suitable temperature, generally between 0 °C and the boiling point of the solvent. The reaction time will depend ter alia on the solvent used, the reaction temperature and the nature of the group L. The reaction may be catalysed by the addition of a base; bases that may be used include organic amines (for example, triethylamine or pyridine) and alkali metal hydroxides, alkoxides, carbonates or hydrides. Suitable leaving groups, L, include halogen (especially chlorine) and hydroxyl. When L represents OH, the reaction between compounds of formulae (II) and (HI) may also be achieved using a suitable coupling agent such as CDI (l,l'-carbonyldiimidazole), DCC (1,3- l o dicyclohexylcarbodiimide) or HOBt ( 1 -hydroxybenzotriazole) .
In process (b) above, the reaction will take place on mixing the reactants in a suitable organic solvent in the presence of a dehydrating agent such as magnesium sulphate or aluminium oxide, or under Dean and Stark conditions, and adding a reducing agent such as is sodium borohydride, sodium cyanoborohydride or sodium triacetoxyborohydride. The reaction time will depend inter alia on the solvent used, the reaction temperature and the
2 nature of the group R .
In process (c) above, the reaction will take place on stirring a mixture of the reactants in a
20 suitable inert organic solvent in the presence of Pd(OAc)2 and (RS)-, (R)- or (S)-BINAP.
Details of this process will be found in the paper by Buchwald et al, J. Org. Chem., 1996, 61, 7240.
It will be apparent to a person skilled in the art that in the above processes it may be 25 desirable to protect an amine or other potentially reactive group. Suitable protecting groups and details of processes for adding and removing such groups may be found by reference to the standard text "Protecting Groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts.
30 The present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.
Salts of compounds of formula (I) may be formed by reacting the free base, or a salt, enantiomer, racemate or tautomer thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuo or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.
Certain novel intermediates of formulae (II), (HI), (V) and (VII) form another aspect of the invention.
The preparation of compounds of formula (II) may be achieved by reaction of a compound of formula (IV) with a compound of formula (VET)
Figure imgf000013_0001
using the methodology of process (b) above.
Alternatively, the preparation of compounds of formula (II) may be achieved by reaction of a compound of formula (VI) with a compound of formula (IX)
Figure imgf000014_0001
using the methodology of process (c) above.
Methods for the preparation of compounds of formulae (HI), (IV), (V), (VI), (VII), (VHI) and (IX) are either known per se or may be achieved using methods that are well known in the art.
Intermediate compounds may be used in protected form. Protecting groups and details of processes for their removal may be found by reference to the standard text "Protecting groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts.
The compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.
The compounds of formula I may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC.
Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.
The compounds of formula (I) may exist in alternative tautomeric forms. Compounds of formula (I) are provided in another tautomeric form or as a mixture thereof.
The compounds of formula (I), and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers, are useful because they possess pharmacological activity in animals. In particular, the compounds are active as inhibitors of the enzyme nitric oxide synthase. More particularly, they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase and as such are predicted to be useful in therapy, for example, as anti-inflammatory agents. They may also have utility as inhibitors of the neuronal isoform of the enzyme nitric oxide synthase.
The compounds and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers are indicated for use in the treatment or prophylaxis of diseases or conditions in which synthesis or oversynthesis of nitric oxide synthase forms a contributory part. In particular, the compounds are indicated for use in the treatment of inflammatory conditions in mammals including man.
Conditions that may be specifically mentioned are: osteoarthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, inflamed joints; eczema, psoriasis, dermatitis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including uveitis and conjunctivitis; lung disorders in which inflammation is involved, for example, asthma, bronchitis, chronic obstructive pulmonary disease, pigeon fancier's disease, farmer's lung, acute respiratory distress syndrome; bacteraemia, endotoxaemia (septic shock), aphthous ulcers, gingivitis, pyresis, pain, meningitis and pancreatitis; conditions of the gastrointestinal tract including inflammatory bowel disease, Crohn's disease, atrophic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome, damage to the gastrointestinal tract resulting from infections by, for example, Helicobacter pylori, or from treatments with non-steroidal anti- inflammatory drugs; and other conditions associated with inflammation.
The compounds will also be useful in the treatment and alleviation of acute pain or persistent inflammatory pain or neuropathic pain or pain of a central origin.
We are particularly interested in the conditions inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease and pain. The compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers may also be useful in the treatment or prophylaxis of diseases or conditions in addition to those mentioned above. For example, the compounds may be useful in the treatment of atherosclerosis, glaucoma, cystic fibrosis, hypotension associated with septic and/or toxic shock, in the treatment of dysfunction of the immune system, as an adjuvant to short-term immunosuppression in organ transplant therapy, in the control of onset of diabetes, in the maintenance of pancreatic function in diabetes, in the treatment of vascular complications associated with diabetes and in cotherapy with cytokines, for example TNF or interleukins.
The compounds of formula (I) may also be useful in the treatment of hypoxia, for example in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as ischaemia, hypoxia, hypoglycaemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia, for example pre-senile dementia, Alzheimer's disease and ADDS-related dementia, Sydenham's chorea, Parkinson's disease, Tourette's Syndrome, Huntington's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Korsakoffs disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, pain, autism, seasonal affective disorder, jet-lag, depression or other symptoms associated with Premenstrual Syndrome (PMS), anxiety and septic shock. Compounds of formula (I) may also be expected to show activity in the prevention and reversal of tolerance to opiates and diazepines, treatment of drug addiction, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of gastrointestinal motility disorders, cancer and in the induction of labour.
We are particularly interested in the conditions stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, migraine, cancer, septic shock and pain.
Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.
The compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, intravenous, topical or other parenteral routes. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
There is also provided a process for the preparation of such a pharmaceutical composition that comprises mixing the ingredients.
The compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may also be advantageously used in combination with a COX-2 inhibitor. Particularly preferred COX-2 inhibitors are Celecoxib and MK-966. The NOS inhibitor and the COX-2 inhibitor may either be formulated together within the same pharmaceutical composition for administration in a single dosage unit, or each component may be individually formulated such that separate dosages may be administered either simultaneously or sequentially.
The invention is illustrated, but in no way limited, by the following examples: Intermediate A
4-.(4-Methyl-2-pyridinyl)amino1-l-piperidinecarboxylic acid ethyl ester 2-Bromo-4-methylpyridine (1.72 g, 0.01 moles), palladium acetate (0.11 g, 0. 5 mmol), racemic BINAP (0.31 g, 0.5 mmol), 4-amino-l-ethoxycarbonylpiperidine (2.0 ml,
12 mmol) and potassium tert-butoxide (1.57 g, 14 mmol) were heated in toluene (50 ml) at 70 °C for 4 h. The cooled solution was diluted with water, extracted with ethyl acetate, the extracts washed with brine, dried (magnesium sulphate) and evaporated. The residue was purified by flash column chromatography eluting with ethyl acetate to yield the title compound as a solid (2.3 g, 88%).
MS (+CI) m/z 264 ([M+H]+).
Intermediate B
4-Methyl-N-(4-piperidinyl -2-pyridinamine
4-[(4-Methyl-2-pyridinyl)amino]-l-piperidinecarboxylic acid ethyl ester (2.2 g, 8.4 mmol) (Intermediate A) was dissolved in ethanol (50 ml) and water (25 ml). Sodium hydroxide (48% w/v, 25 ml) was added and the solution was refluxed for 20 h, cooled and extracted with ethyl acetate. The residue was purified by flash column chromatography eluting with 5% methanol in dichloromethane to yield the title compound as an oil (1.5 g).
MS (+CI) m/z 192 ([M+H]+).
Intermediate C
4-r(4-Methoχy-2-pyridinyl amino1-l-piperidinecarboxylic acid ethyl ester This was prepared by the same procedure used for Intermediate A, but using 2-chloro-4-methoxypyridine, to give the title compound as a brown oil.
MS (+CI) m/z 280 ([M+H]+). Intermediate D
4-Methoxy-N-,4-piperidinyl)-2-pyridinamine
This was prepared by the same procedure used for Intermediate B, but using 4-[(4-methoxy-2-pyridinyl)amino]-l-piperidinecarboxylic acid ethyl ester (Intermediate C), to give the title compound as an off-white solid.
MS (+CI) m/z 208 ([M+H]+).
Intermediate E
4-Methoxy-N-ri-(phenylmethyl)-3-pyrrolidinyIl-2-pyridinamine A mixture of 2-bromo-4-methylpyridine (5.76 mmol, 986 mg), l-(phenylmethyl)-3- pyrrolidinamine (1.12 g, 1.1 equivalents), racemic BINAP (180 mg, 5 mol%), palladium acetate (65 mg), potassium tert-butoxide (903 mg) in toluene (30 ml) was heated to 70 °C for 16h, cooled, diluted with water and extracted three times with ethyl acetate. The combined extracts were dried over sodium sulphate and evaporated. The residue was purified by flash column chromatography eluting with 5-10% methanol in dichloromethane to yield the title compound as a yellow oil (700 mg).
MS (+CI) m/z 268 ([M+H]+).
Intermediate F
N-(4-Methoxy-2-pyridyl)pyrrolidin-3-amine
4-Methoxy-N-[l-(phenylmethyl)-3-pyrrolidinyl]-2-pyridinamine (700 mg, 2.62 mmol), palladium hydroxide (350 mg), cyclohexene (35 ml) and ethanol (70 ml) were heated to reflux for 16h, cooled and filtered through celite. Evaporation gave the title compound as a yellow oil (464 mg).
MS (+CI) m/z 178 ([M+H]+). Intermediate G
N'- Φ-Methyl-Σ-pyridinyl)- 1 ,3-propanedi amine
A mixture of palladium acetate (106 mg), racemic BINAP (291 mg) and 2-bromo-4- methylpyridine (9.63 mmol, 1.07 ml) was heated in toluene (66 ml) to 70 °C for 20 min., propane- 1, 3 -diamine (1.00 ml, 12 mmol) and sodium tert-butoxide (1.11 g) were added, and the mixture heated for a further 3 h. After cooling, the solution was diluted with water, extracted four times with ethyl acetate, these extracts discarded, and extraction continued with dichloromethane (six times). The dichloromethane extracts were combined, dried over sodium sulphate and evaporated to give the amine as a yellow oil which solidified on standing.
MS (+CI) m/z 166 ([M+H]+).
Intermediate H
N'-(4-Methoxy-2-pyridinyl)- 1 ,3-ρropanediamine
This was prepared using the same method as for Intermediate G but starting with
4-methoxy-2-chloropyridine to afford the title compound as a yellow oil.
MS (+CI) m/z 183 ([M+H+]).
Intermediate I
4-f ,4-Chloro-2-pyridinyl)arnino1-l-piperidinecarboxylic acid ethyl ester This was prepared by the same method as for Intermediate A but using 2,4-dichloropyridine to afford the title compound as a yellow oil.
MS (+CI) m/z 284/286 ([M+H]+). Intermediate J
4-Chloro-N-(4-piperidinyl)-2-pyridinamine
This was prepared by the same method as for Intermediate B but using 4-[(4-chloro-2- pyridiriyl)amino]-l-piperidinecarboxylic acid ethyl ester to afford the title compound as a yellow oil.
MS (+CI) m/z 212/214 ([M+H]+).
Intermediate K
l-(4-ChlorobenzovD-4-methylenepiperidine
Methyl phosphonium bromide (7.1 g, 0.02 mol) was suspended in tetrahydrofuran (75 ml) and 2M butyl lithium (10 ml in hexane, 0.02 mol) added at 0 °C. After 1 h at room temperature the solution was added dropwise over 30 min. to a solution of l-(4-chlorobenzoyl)-4-piperidone (2.38 g, 0.01 mol) in tetrahydrofuran (75 ml). After 16 h, water was added, followed by extraction with ether three times. The extracts were combined, dried over magnesium sulphate and evaporated. The residue was purified by flash column chromatography eluting with 30% ethyl acetate in hexane to yield the title compound as an oil. MS (+EI) m/z 236/238 (M+).
Intermediate L
4- Azido- 1 -(4-chlorobenzoyl)-4-methylpiperidine Sodium azide (0.5 g, 7.65 mmol) was added to l-(4-chlorobenzoyl)-4-methylenepiperidine (0.6 g, 2.6 mmol) in tetrahydrofuran/water (1: 1, 10 ml) followed by mercuric acetate (0.83 g, 2.6 mmol). The mixture was heated to 90 °C for 24 h, cooled to 0 °C, and IN aqueous sodium hydroxide (6.8 ml) added, followed by sodium borohydride (50 mg, 1.4 mmol) in IN aqueous sodium hydroxide over 5 minutes. Stirring was continued for 20 min., then the mixture was extracted with ether twice, dried over magnesium sulphate and evaporated. The residue was purified by flash column chromatography eluting with 30% ethyl acetate in hexane to yield the title compound as an oil.
MS (+CI) m/z 279/281 ([M+H]+).
Intermediate M
l-("4-Chlorobenzoyl)-4-methyl-4-piperidinamine 4-Azido-l-(4-chlorobenzoyl)-4-methylpiperidine (0.31 g, 1.1 mmol) and triphenylphosphine (0.32 g, 1.2 mmol) were refluxed in 33% aqueous dioxane for 24h. The reaction mixture was evaporated, diluted with dilute hydrochloric acid and extracted with ethyl acetate. The acid layer was basified with aqueous potassium carbonate, extracted with dichloromethane three times, the combined dichloromethane layers dried over magnesium sulphate and evaporated to give the title compound as an oil (0.23 g). MS (+CI) m/z 253/255 ([M+H]+).
Example 1
N-ri-(3-FuranylcarbonylV4-piperidinyll-4-methyl-2-pyridinamine A mixture of 4-methyl-N-(4-piperidinyl)-2-pyridinamine (0.19 g, 1 mmol) (Intermediate B), 3-furancarboxylic acid (0.12 g, 1.1 mmol), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (0.7 g, 1.5 mmol) and Hunig's base (0.52 ml, 3 mmol) was stirred in dichloromethane for 20 h. The solution was diluted with water, separated and the organic layer dried (magnesium sulphate) and evaporated. The residue was purified by flash column chromatography eluting with ethyl acetate to yield the product, which was dissolved in ethanol, 4N hydrochloric acid in dioxane added and the solution evaporated. Trituration with ether gave the title compound as the hydrochloride salt (0.18 g).
MS (+CI) m/z 286 ([M+H]+);
300MHz *H NMR (d6-DMSO) 8.66 (IH, br.s), 8.06 (IH, s), 7.83 (IH, d), 7.76 (IH, s), 6.90 (IH, s), 6.74 (IH, d), 6.67 (IH, s), 3.99-3.97 (IH, m), 3.64-3.58 (IH, m), 3.2-3.0 (3H, m), 2.34 (3H, s), 1.99 (2H, d), 1.43 (2H, ddd). Example 2
N-r 1 -(4-Cvanobenzoyl)-4-piperidinvn-4-methyl-2-pyridinamine A mixture of 2-amino-4-methylpyridine (1.01 g, 9.4 mmol) and l-(4-cyanobenzoyl)piperidin-4-one (1.35 g, 9.4 mmol) were heated neat to 120 °C for 4 h. The reaction mixture was then cooled to 40-50 °C, and tetrahydrofuran was cautiously added to dissolve the mixture. Sodium borohydride (0.39 g, 10 mmol) was added at room temperature and stirring continued for 16 h, then dilute aqueous hydrochloric acid was added, followed by solid sodium bicarbonate. After extraction with ethyl acetate, the organic extracts were dried over sodium sulphate and evaporated. The residue was purified by flash column chromatography eluting with 2% methanol in dichloromethane to yield the title compound as a golden oil (0.09 g).
MS (+CI) m/z 321 ([M+H]+);
300MHz lU NMR (d6-DMSO) 7.94 (2H, d), 7.8 (IH, d), 7.56 (2H, d), 6.3 (2H, m), 4.32 (IH, m), 3.96 (IH, m), 3.44 (IH, m), 3.18-3.06 (2H, m), 2.12 (3H, s), 1.99-1.82 (2H, m).
Example 3
4-rr3-r(4-Methoxy-2-pyridinyl')aminol-l-pyrrolidinyncarbonynbenzonitrile 4-Cyanobenzoic acid chloride (160 mg, 0.963 mmol) was added with stirring to a solution of N-(4-methoxy-2-pyridyl)pyrrolidin-3-amine (155 mg, 0.876 mmol) and triethylamine (0.3 ml) in dichloromethane. After 1 h, the solution was diluted with water, extracted twice with dichloromethane and the combined extracts dried over sodium sulphate and evaporated. The residue was purified by flash column chromatography eluting with 2 - 4% methanol in dichloromethane to yield the title compound as a colourless film which was treated with IN HC1 in diethyl ether to precipitate a white solid of the title compound hydrochloride salt.
MS (+CI) m/z 307 ([M+H]+);
400MHz H NMR (d6-DMSO) (a 1:1 mixture of rotamers) 13.48 (IH, br.s), 9.13 (0.5H, br.s), 8.96 (0.5H, br.s), 7.97-7.92 (2H, m), 7.88 (0.5H, d), 7.80 (0.5H, d), 7.72 (2H, d), 6.95 (0.5H, s), 6.87 (0.5H, s), 6.79 (0.5H, d), 6.75 (0.5H, d), 4.47 (0.5H, br.s), 4.39 (0.5H, br.s), 3.86-3.81 (IH, m), 3.65-3.3 (3H, m), 2.36 (1.5H, s), 2.32 (1.5H, s), 2.4-2.2 (IH, m), 2.03- 2.96 (IH, s).
Example 4
4-..4-r(4-Methoxy-2-pyridinyl)amino,-l-piperidinyllcarbonyl1benzonitrile A solution of 4-cyanobenzoic acid (148 mg, 1 mmol) in N,N-dimethylformamide (4 ml) was treated with carbonyldiimidazole (196 mg, 1.2 mmol). After stirring for 30 minutes, 4-methoxy-N-(4-piperidinyl)-2-pyridinamine (1 mmol) in N,N-dimethylformamide (2 ml) was added. After a further 30 min, the solution was diluted with water, extracted three times with ethyl acetate, the combined extracts dried (sodium sulphate), evaporated and purified by normal phase HPLC eluting with 0 - 10% ethanol/dichloromethane to yield, after trituration with diethyl ether, a white solid (177 mg). MS (+CI) ra/z 337 ([M+H]+);
300MHz lU NMR (d6-DMSO) 7.95 (2H, d), 7.84 (IH, d), 7.61 (2H, d), 6.55 (IH, dd),
6.45 (IH, s), 4.4 (IH, br.s), 4.0 (IH, br.s), 3.91 (IH, br.s), 3.5 (IH, br.s), 3.2 (IH, br.s), 3.15-3.0 (IH, br.m), 2.1-2.0 (IH, br.m), 1.95-1.85 (2H, br.m), 1.55 (2H, br.m).
Following the general method of Example 4 but using the acid stated, the compounds of Examples 5 to 39 were prepared.
Example 5
5 N-l" 1 -(4-Bromobenzoyl)-4-piperidinyl1-4-methoxy-2-pyridinamine
Using 4-bromobenzoic acid. The hydrochloride salt of the title compound was obtained as a white solid after trituration with IN HC1 in ether.
MS (+CI) m/z 391 ([M+H]+);
400MHz !H NMR (d6-DMSO) 8.53 (IH, br.s), 7.84 (IH, d), 7.66 (2H, d), 7.38 (2H, d), o 6.54 (IH, dd), 6.44 (IH, s), 4.2 (IH, br.s), 3.98-3.96 (IH, br.d), ), 3.70 (3H, s), 3.6 (IH, br.s), 3.2- 3.0 (2H, br.s), 2.05 -1.95 (2H, br.m), 1.5-1.4 (2H, br.s). Example 6
N-[l -(4-Chlorobenzoyl)-4-piperidinyll-4-methoxy-2-pyridinamine Using 4-chlorobenzoic acid. A white solid.
MS (+CI) m/z 347 ([M+H]+);
400MHz lH NMR (d6-DMSO) 7.77 (IH, d, J 6Hz), 7.52 (IH, d, J 8Hz), 7.41 (IH, d, J
8Hz), 6.38 (IH, d, J 6.8Hz), 6.13-6.11 (IH, m), 5.98 (IH, s), 4.4-4.2 (IH, br.m), 4.0-3.9 (IH, br.m), 3.70 (3H, s), 3.6-3.5 (IH, br.m), 3.2-3.0 (2H, br.m), 2.0-1.8 (2H, br.m), 1.4-1.3 (2H, br.m).
Example 7
4-Methoxy-N-ri-(2-thienylcarbonyl)-4-piperidinyll-2-pyridinamine Using 2-thiophenecarboxylic acid. A white powder. MS (+CI) m/z 318 ([M+H]+);
400MHz H NMR (d6-DMSO) 7.77 (IH, d, J 6Hz), 7.75 (IH, d, J 6Hz), 7.39-7.38 (IH, m), 7.12 (IH, dd, J 3.6, 4.8Hz), 6.40 (IH, d, J 8Hz), 6.13-6.11 (IH, m), 5.98 (IH, s), 4.18 (2H, br.s), 4.00 (IH, s), 3.70 (3H, s), 3.20 (IH, br.s), 1.95 (2H, d, J 9Hz), 1.42-1.32 (2H, m).
Example 8
N-ri-f(5-Chloro-2-thienyl)carbonyll-4-piperidinyl1-4-methoxy-2-pyridinamine Using 2-(5-chloro)thiophenecarboxylic acid. A white powder. MS (+CI) m/z 352 ([M+H]+);
400MHz *H NMR (d6-DMSO) 7.78 (IH, d), 7.30 (IH, d), 7.15 (IH, d), 6.40 (IH, d), 6.11
(IH, dd), 5.98 (IH, d), 4.15 (2H, d), 4.01-3.99 (IH, br.m), 3.70 (3H, s), 1.95 (lh, dm), 1.37 (IH, dd). Example 9
4-rr4-r(4-Methoxy-2-pyridinyl)aminol-l-piperidinyπcarbonyl]benzenesulphonamide Using 4-sulphonamidobenzoic acid. A white powder.
MS (+CI) π7z 391 ([M+H]+);
400MHz lH NMR (d6-DMSO) 7.88 (2H, d, J 8.4Hz), 7.77 (IH, d, J 6Hz), 7.57 (2H, d, J
8.4Hz), 7.45 (2H, s), 6.38 (IH, d, J 7.6Hz), 6.11 (IH, dd, J 2.4, 6Hz), 5.98 (IH, s), 4.34 (IH, br.s), 3.98 (IH, br.s), 3.70 (3H, s), 3.5-3.4 (IH, br.m), 3.2-3.0 (2H, br.m), 2-1.8 (2H, m), 1.4-1.2 (2H, m).
Example 10
N-ri-r(6-Chloro-3-pyridinyl)carbonyll-4-piperidinyn-4-methoxy-2-pyridinamine Using 6-chloronicotinic acid. A white powder. MS (+CI) m/z 347 ([M+H]+);
400MHz H NMR (d6-DMSO) 8.46 (IH, s), 7.90 (IH, dd), 7.77 (IH, d), 7.63 (IH, d), 6.38
(IH, d), 6.12 (IH, dd), 5.98 (IH, s), 4.29 (IH, br.s), 3.99-3.96 (IH, m), 3.70 (3H, s), 3.52 (IH, br.s), 3.30-3.0 (2H, br.m), 2.0-1.8 (2H, m), 1.5-1.3 (2H, m).
Example 11
4-Methoxy-N- F 1 -(2-pyrazinecarbonyl -4-piρeridinyll -2-pyridinamine Using pyrazine carboxylic acid. A white powder.
MS (+CI) m/z 314 ([M+H]+);
400MHz !H NMR (d6-DMSO) 8.30 (IH, s), 8.74 (IH, s), 8.67 (IH, s), 7.77 (IH, d), 6.41
(IH, d), 6.12 (IH, dd), 5.97 (IH, s), 4.35 (IH, d), 4.02-4.01 (IH, m), 3.71 (3H, s), 3.70- 3.64 (IH, m), 3.22 (IH, dt), 3.10 (IH, dt), 2.01 (IH, br.d), 1.86 (IH, br.d), 1.39 (IH, dq). Example 12
N-ri-(3,4-Dichlorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine
Using 3,4-dichlorobenzoic acid. A white solid.
MS(+ Cl) m/z 380/382 ([M + H]+);
300MHz H NMR (d6 - DMSO) 7.77 (IH, d, J 6Hz), 7.72 (IH, d, J 8Hz), 7.66 (IH, d, J
2Hz), 7.38 (IH, dd, J 8Hz, J 2Hz), 6.37 (IH, d, J 7.5Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98
(IH, d, J2Hz), 4.29 (IH, br.m), 3.97 (IH, br.m), 3.12 (2H, br.m), 1.92 (2H, br.m), 1.36
(2H, br.m)
Example 13
4-Methoxy-N-r 1 -(3-thienylcarbonyl)-4-piperidinyll-2-pyridinamine Using thiophene-3-carboxylic acid. A white solid. MS(+ Cl) m/z 318 ([M+H]+);
300 MHz H NMR (d6 - DMSO) 7.76 (2H, m), 7.61 (IH, m), 7.19 ( IH, dd, J 5Hz, J 1Hz), 6.38 ( IH, d, I 8Hz ), 6.12 (IH, dd, J 6Hz, J 2Hz ), 5.98 (IH, d, J 2Hz), 4.2 (IH, br.m), 3.99 ( 2H, br.m), 3.7 (3H, s), 3.1 ( 2H, br.m) 1.92 (2H, br.d), 1.34 (2H, br.m)
Example 14
4-Methoxy-N-. l-(4-methoxybenzovI,-4-piperidinyl1-2-pyridinamine Using 4-methoxybenzoic acid. A white solid.
MS(+ Cl) ra/z 342 ([M + H]+);
300MHz H NMR (d6-DMSO) 7.77 (IH, d, J 6Hz), 7.35 (2H, d, J 9Hz), 6.99 (2H, d, J
9Hz), 6.37 (IH, d, J 8Hz), 6.11 (IH, dd, J 6Hz, J 2Hz), 5.97 (IH, d, J 2Hz), 4.2 (IH, br.m), 3.97 (2H, br.m), 3.79 (3H, s), 3.70 (3H, s), 3.09 (2H, br.m), 1.90 (2H, br.m), 1.33 (2H, br.m). Example 15
N-π-((5-Bromo-2-thienyl)carbonyl}-4-piperidinyll-4-methoxy-2-pyridinamine Using 5-bromothiophene-2-carboxylic acid. A white solid. MS(+CI) m/z 396/398 ([M + H]+);
300MHz lH NMR (d6-DMSO) 7.78 (IH, d, J 6Hz), 7.25 (2H, s), 6.40 (IH, d, J 8Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2Hz), 4.14 (2H, br.d), 4.02 (IH, br.m), 3.71 (3H, s), 3.21 (2H, br.m), 1.95 (2H, br.m), 1.37 (2H, br.m).
Example 16
4-Methoxy-N-F 1-1 (2-,4-pyridinyl)-4-thiazolyl)carbonyl )-4-piperidinyll-2-pyridinamine Using 2-(pyridin-4-yl)thiazole-4-carboxylic acid. A pale yellow solid.
MS(+CI) m/z 396 ([M+H]+); 300 MHz lH NMR (d6-DMSO) 8.74 (2H, dd, J 4.5Hz, J 1.5Hz), 8.30 (IH, s), 7.92 (2H, dd, J 4.5Hz, J 1.5Hz), 7.78 (IH, d, J 6Hz), 6.43 (IH, d, J 8Hz), 6.13 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2Hz), 4.37 (IH, br.m), 4.08 (2H, br.m), 3.71 (3H, s), 3.33 (IH, br.m), 3.08 (IH, br.m), 1.99 (2H, br.m ), 1.44 (2H, br.m).
Example 17
N-r 1 -(3 ,5-Dibromobenzoyl)-4-piperidinyll-4-methoxy-2-pyridinamine Using 3,5-dibromobenzoic acid. A white solid.
MS(+CI) m/z 468/470/472 ([M+H]+);
300MHz H NMR (d6-DMSO) 7.94 (IH, t, J 2Hz), 7.77 (IH, d, J 6Hz), 7.61 (2H, d, J
2Hz), 6.36 (IH, d, J 8Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2Hz), 4.26 (IH, br.m), 3.96 (IH, br.m), 3.71 (3H, s), 3.46 (IH, br.m), 3.19 (IH, br.m), 3.04 (IH, br.m), 1.96 (IH, br.m), 1.88 (IH, br.m), 1.36 (2H, br.m). Example 18
N-ri-(4-Chloro-3-iodobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine Usin lgb 4-chloro-3-iodobenzoic acid. A white solid. MS(+CI) m/z 472/474 ([M+H] );
300MHz H NMR (d6-DMSO) 7.92 (IH, d, J 2Hz), 7.77 (IH, d, J 6Hz), 7.65 (IH, d, J 8Hz), 7.42 (IH, dd, J 8Hz, J 2Hz), 6.37 (IH, d J 8Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2Hz), 4.27 (IH, br.m), 3.95 (IH, br.m), 3.70 (3H, s), 3.51 (IH, br.m), 3.12 (2H, br.m), 1.92 (2H, br.m), 1.36 (2H, br.m).
Example 19
N-ri-(3-Isoquinolinylcarbonyl)-4-piperidinyll-4-methoxy-2-pyridinamine Using 3-isoquinoline carboxylic acid. A white solid. MS (+CI) m/z 363 ([M+H]+);
300MHz H NMR (d6-DMSO) 9.34 (IH, s), 8.20 (IH, d, J 8Hz), 8.08 (2H, m), 7.86 (IH, t), 7.77 (2H, m), 6.43 (IH, d, J 8Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2Hz), 4.42 (IH, br.d), 4.02 (IH, br.m), 3.76 (IH, br.m), 3.71 (3H, s), 3.24 - 3.06 (2H, m), 2.03 (IH, br.m), 1.85 (IH, br.m), 1.42 (2H, br.m).
Example 20
4-Methoxy-N-ri-(6-quinolinylcarbonyl)-4-piperidinyn-2-pyridinamine Using 6-quinolinecarboxylic acid. A white solid. MS (+CI) m/z 363 (_M+H]+);
300MHz *H NMR (d6-DMSO) 8.9 (IH, d, J 3Hz), 8.46 (IH, d, J 8Hz), 8.05 (2H, m), 7.76 (2H, m), 7.61 (IH, m), 6.41 (IH, d, J 8Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.99 (IH, d, J 2Hz), 4.39 (IH, br.m), 4.01 (IH, br.m), 3.71 (3H, s), 3.65 (IH, br.m), 3.2 (2H, br.m), 1.95 (2H, br.m), 1.41 (2H, br.m). Example 21
N-π-(3.5-Difluorobenzoyl)-4-piperidinyll-4-methoxy-2-pyridinamine Using 3,5-difluorobenzoic acid. A white solid. MS(+CI) m/z 348 ([M+H]+);
300MHz H NMR(d6-DMSO) 7.77 (IH, d, J 6Hz), 7.35 (IH, t of t), 7.15 (2H, m), 6.37 (IH, d, J 8Hz), 6.12 (IH, dd, J 6Hz,J 2Hz), 5.98 (IH, d, J 2Hz), 4.28 (IH, br.m), 3.95 (IH, br.m), 3.70 (3H, s), 3.39 (IH, br.m), 3.11 (2H, br.m), 1.91 (2H, br.m), 1.36 (2H, br.m).
Example 22
4-Methoxy-N-ri-[(5-methyl-l-phenyl-lH-pyrazol-4-yl)carbonyl1-4-piperidinyll-2- pyridinamine
Using 5-methyl-l -phenyl- lH-pyrazole-4-carboxylic acid. A white solid. MS (+CI) m/z 392 ([M+H]+);
400MHz H NMR (d6-DMSO) 7.78 (IH, d, J 6Hz), 7.75 (IH, s), 7. 58-7.45 (5H, m), 6.39
(IH, d, J 8Hz), 6.13-6.11 (IH, m), 5.98 (IH, d, J 2Hz), 4.25-3.8 (3H, m), 3.71 (3H, s), 3.15 (2H, br.m), 2.35 (3H, s), 1.97-1.94 (2H, m), 1.41-1.31 (2H, m).
Example 23
N-ri-r4-(Dimethylamino benzoyll-4-piperidinyll-4-methoxy-2-pyridinamine Using 4-dimethylaminobenzoic acid. A white solid. MS (+CI) m/z 355 ([M+H]+); 400MHz H NMR (d6-DMSO) 7.77 (IH, d, J 6Hz), 7.26 (2H, d, J 9Hz), 6.71 (2H, d, J 9Hz), 6.37 (IH, d, J 8Hz), 6.11 (IH, dd, J 8Hz, J 2Hz), 5.96 (IH, d, J 2Hz), 4.1-3.9 (3H, br.m), 3.7 (3H, s), 3.08 (2H, br.m), 2.94 (6H, s), 1.9 (2H, m), 1.32 (2H, m). Example 24
4-Methoxy-N-ri-(3-quinolinylcarbonyl)-4-piperidinyll-2-pyridinamine Using quinoline-3-carboxylic acid. A white solid.
MS(+CI) m/z 363 ([M+H]+);
400MHz lH NMR (d6-DMSO) 8.91 (IH, d, J 2Hz), 8.45 (IH, d, J 2Hz), 8.09-8.06 (2H, m), 7.87-7.83 (IH, m), 7.77 (IH, d, J 6Hz), 7.71-7.67 (IH, m), 6.41 (IH, d, J 8Hz), 6.12 (IH, dd, J 8Hz, J 2Hz), 6.0 (IH, d, J 2Hz), 4.39 (IH, br. m), 4.02 (IH, br.m), 3.71 (3H, s), 3.66 (IH, br.m), 3.4-3.1 (2H, br.m), 2.0-1.9 (2H, br.m), 1.44 (2H, br.m).
Example 25
4-Methoxy-N-ri-r(6-methyl-3-pyridinyl carbonyll-4-piperidinyll-2-pyridinamine Using 6-methylpyridine-3-carboxylic acid. A white solid. MS(+CI) m/z 327 ([M+H]+);
400MHz H NMR (d6-DMSO) 8.46 (IH, t, J 1Hz), 7.77 (IH, d, J 6Hz), 7.7 (IH, dd, J 7Hz,
J 2Hz) 7.33 (IH, d, J 8Hz), 6.38 (IH, d, J 8Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2.4Hz), 4.31 (IH, br.m), 3.98 (IH, br.m), 3.7 (3H, s), 3.55 (IH, br.m), 3.3-3.0 (2H, br.m), 2.5 (3H, s), 2.0-1.8 (2H, br.m), 1.36 (2H, br.m).
Example 26
4-Methoxy-N-l" 1 -f 4-( lff-pyrrol- 1 -yl benzoyll-4-piperidinyll-2-pyridinamine Using 4-(l -pyrrol-l-yl) benzoic acid. A white solid. MS (+CI) m/z 377 (_M+H]+);
400MHz H NMR (d6-DMSO) 7.77 (IH, d, J 6Hz), 7.66 (2H, d, J 8Hz), 7.47 (2H, d, J
8Hz), 7.44-7.43 (2H, m), 6.38 (IH, d, J 8Hz), 6.3 (2H, m), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2Hz), 4.3 (IH, br.m), 4.0 (IH, br.m), 3.7 (3H, s), 3.66 (IH, br.m), 3.13 (2H, br.m), 1.97 (2H, br.m), 1.37 (2H, br.m). Example 27
N-. l-(4-Iodobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine Using 4-iodobenzoic acid. A white solid. MS (+CI) m/z 438 ([M+H]+);
400MHz H NMR (d6-DMSO) 7.83-7.81 (2H, m), 7.77 (IH, d, J 6Hz), 7.2-7.17 (2H, m),
6.37 (IH, d, J 8Hz), 6.13-6.1 (IH, m), 5.97 (IH, d, J 2Hz), 4.3 (IH, br.m), 4.0-3.94 (IH, m), 3.7 (3H, s), 3.52 (IH, br.m), 3.2-3.3 (2H, br.m), 2-1.8 (2H, br.m), 1.4-1.2 (2H, br.m).
Example 28
N-l" 1 -( l-Benzothiophen-2-ylcarbonyl)-4-piperidinyll-4-methoxy-2-pyridinamine Using l-benzothiophene-2-carboxylic acid. A white solid.
MS(+CI) ra/z 368 ([M+H]+); 400MHz H NMR (d6-DMSO) 8.03-8.01 (IH, m), 7.95-7.93 (IH, m), 7.78 (IH, d, J 6Hz),
7.08 (IH, s), 7.47-7.42 (2H, m), 6.42 (lH,.d, J 8Hz), 6.14-6.12 (IH, m), 5.99 (IH, d, J 2Hz), 4.21 (2H, br.m), 4.03 (IH, m), 3.7 (3H, s), 3.25 (2H, br.m), 2-1.97 (2H, m), 1.47- 1.37 (2H, br.m).
Example 29
N-r 1 -f ( 4 -Ethvir l , l -biphenyll-4-yl)carbonyll-4-piperidinyll-4-methoxy-2-pyridinamine Using 4'-ethyl[l, -biphenyl]-4-carboxylic acid. A white solid. MS(+CI) m/z 416 ([M+H]+);
400MHz !H NMR (d6-DMSO) 7.77 (IH, d, J 6Hz), 7.72 (2H, dd, 6Hz, J 2Hz), 7.62 (2H, dd, J 6Hz, J 2Hz), 7.46 (2H, dd, J 6Hz, J 2Hz), 7.32 (2H, d, J 8Hz), 6.39 (IH, d, J 7Hz), 6.12 (IH, dd, J 6Hz, J 2Hz), 5.98 (IH, d, J 2Hz), 4.34 (IH, br.m), 4.0 (IH, br.m), 3.7 (3H, s), 3.65 (IH, br.m), 3.3-3 (2H, br.m), 2.65 (2H, q, J 8Hz), 1.37 (2H, br.m), 1.22 (3H, t, J 8Hz). Example 30
N-ri-(lH-1.2.3-Benzotriazol-5-ylcarbonyπ-4-piperidinyll-4-methoxy-2-pyridinamine Using lH-l,2,3-benzotriazole-5-carboxylic acid. A white solid. MS(+CI) m/z 353 ([M+H]+);
400MHz lH NMR (d6-DMSO) 7.93 (IH, d, J 9Hz), 7.9 (IH, s), 7.77 (IH, d, J 6Hz), 7.38
(IH, dd, J 8Hz, J 1Hz), 6.4 (IH, d, J 8Hz), 6.11 (IH, dd, J 6Hz, J 2Hz), 6.0 (IH, d, J 2Hz), 4.0 (IH, br.m), 3.7 (3H, s), 3.6-3.1 (4H, br.m), 1.9 (2H, br.m), 1.4 (2H, br.m).
Example 31
4-Methoxy-N-ri-r4-(l-methylethyl)benzoyll-4-piperidinyll-2-pyridinamine Using 4-(l-methylethyl)-benzoic acid. A white solid.
MS(+CI) "7z 354 ([M+H]+); 400MHz !H NMR (d6-DMSO) 7.77 (IH, d, J 6Hz), 7.33-7.29 (4H, m), 6.37 (IH, d, J
8Hz), 6.11 (IH, dd, J 6Hz, J 2Hz), 5.97 (IH, d, J 2Hz), 4.3 (IH, br.m), 3.98 (IH, br.m), 3.7 (3H, s), 3.6 (IH, br.m), 3.1 (IH, br.m), 2.92 (IH, quin), 1.9 (2H, br.m), 1.3 (2H, br.m), 1.23 (6H, d, J 7Hz).
Example 32
4-Methoxy-N-r 1 -( 1 ,2,3-thiadiazol-4-ylcarbonyl)-4-piperidinyll-2-pyridinamine Using l,2,3-thiadiazole-4-carboxylic acid. The hydrochloride salt of the title compound was obtained as a white solid. MS(+CI) m/z 320 ([M+H]+);
300MHz TH NMR (d6-DMSO) 13.02 (NH, br.s), 9.57 (IH, s), 8.54 (NH, br.s), 7.86-7.84
(IH, d), 6.55-6.52 (IH, dd), 6.45-6.44 (IH, d), 4.51-4.46 (IH, d), 4.03 (IH, m), 3.91 (3H, s), 3.39 (2H), 3.16-3.11 (IH), 2.99 (IH, d), 1.95 (lH,d), 1.58-1.48 (2H, m). Example 33
4-Methoxy-N-ri-(3-pyridinylcarbonyl)-4-piperidinyl]-2-pyridinamine Using nicotinic acid. A white solid.
MS(+CI) m/z 313 ([M+H)+];
300MHz HNMR (d6-DMSO) 8.65-8.63 (IH, dd), 8.60-8.59 (IH, dd), 7.84-7.80 (IH),
7.78-7.76 (IH, d), 7.50-7.46 (IH, m), 6.39-6.37 (lH,d), 6.13-6.10 (IH, dd), 5.98-5.97 (IH, d), 4.31 (IH, br.s), 3.99-3.94 (IH, m), 3.70 (3H, s), 3.57-3.51 (IH, m), 3.07 (2H, m), 1.99- 1.89 (2H, m), 1.38 (2H, br.s).
Example 34
4-Methoxy-N-. l-(2-pyridinylcarbonyl -4-piperidinyl]-2-pyridinamine Using picolinic acid. A white solid. MS(+CI) m/z 313 (_M+H]+);
300MHz H NMR (d6-DMSO) 8.59-8.57 (lH,m), 7.95-7.89 (IH, m), 7.77-7.76 (IH, d),
7.55-7.52 (IH, d), 7.49-7.45 (IH, q), 6.41-6.38 (NH, d), 6.12-6.10 (IH, dd), 5.97-5.96 (IH, d), 4.37-4.33 (IH, br.d), 4.01-3.99 (IH, m), 3.70 (3H, s), 3.65-3.61 (IH, d), 3.19-3.01 (2H, m), 2.01-1.82 (2H, m), 1.43-1.32 (2H, br.q).
Example 35
N-f 1 -(3-Isoxazolylcarbonyl -4-piperidinyll-4-methoxy-2-pyridinamine Using 3-isoxazolecarboxylic acid. A white solid. MS(+CI) m/z 303 ([M+H]+);
300MHz HNMR (d6-DMSO) 9.08-9.07 (IH, d), 7.78-7.76 (IH, d), 6.81-6.81 (IH, d),
6.42-6.39 (NH, d), 6.13-6.11 (IH, dd), 5.97-5.96 (IH, d), 4.34-4.30 (IH, m), 4.03-4.01(lH, m), 3.85-3.80 (IH, m), 3.70 (3H, s), 3.23-3.22 (IH, m), 3.14-3.05 (IH, m), 2.01-1.89 (2H, m), 1.42-1.30 (2H, m). Example 36
4-Methoxy-N-ri-r(5-methyl-2-pyrazinyl)carbonyll-4-piperidinyll-2-pyridinamine Using 5-methyl-2-pyrazine carboxylic acid. A white solid.
MS(+CI) m/z 328 ([M+H]+);
300MHz 1HNMR (d6-DMSO) 8.69-8.68 (IH, d), 8.56-8.55 (IH, d), 7.78-7.76 (IH, d),
6.41-6.39 (NH, d), 6.13-6-6.10 (IH, dd), 5.97-5.96 (IH, d), 4.36-4.32 (IH, br.d), 4.02-3.99 (IH, m), 3.70 (3H, s), 3.25-3.04 (2H, m), 2.55 (3H, s), 2.02-1.99 (IH, m), 1.87-1.84 (IH, m), 1.44-1.34 (2H, m).
Example 37
N-ri-r4-(Aminomethyl)benzoyll-4-piperidinyll-4-methoxy-2-pyridinamine Using 4-(9-fluorenylmethoxycarbonyl)aminomethyl)benzoic acid together with the following work-up procedure. The reaction mixture was diluted with water and ethyl acetate and the organic layer was washed with 2M hydrochloric acid. The aqueous layer was extracted three times with ethyl acetate. The aqueous layer was then concentrated down and the golden oil obtained was purified via super critical fluid chromatography. This gave the title compound as a white solid. MS(+CI) m/z 341 ([M+H]+);
300MHz H NMR (d6-DMSO) 7.86-7.77 (IH, d), 7.39-7.41 (2H, d), 7.35-7.32 (2H, d),
6.38-6.35 (IH, d), 6.12-6.10 (IH, dd), 5.97-5.96 (IH, d), 4.30-4.28 (IH, m), 3.99 (IH, m), 3.79 (2H, s), 3.70 (3H, s), 3.56 (IH, m), 3.18 (2H, m), 1.89 (2H, m), 1.24 (2H, m).
Example 38
4-Methoxy-N-ri-(4-pyridinylcarbonyl)-4-piperidinyll-2-pyridinamine Using isonicotinic acid. A white solid.
MS(+CI) 313 ([M+H]+); 300MHz !H NMR (d6-DMSO) 8.69-8.67 (2H, d), 7.84-7.81 (IH, d), 7.40-7.38 (2H, dd),
6.44-6.42 (IH, d), 6.28 (IH, s), 6.10 (2H, s), 4.40-4.37 (IH, m), 3.85 (3H, s), 3.32 (3H), 2.04-1.86 (2H, m), 1.44-1.41 (2H, m).
Example 39
N-ri-(3-Amino-4-chlorobenzoyl)-4-piperidinyll-4-methoxy-2-pyridinamine Using 3-amino-4-chlorobenzoic acid. A white solid.
MS(+CI) m/z 361 ([M+H]+); 300MHz H NMR (d6-DMSO) 7.77-7.75 (IH, d), 7.24-7.21 (IH, d), 6.77-6.77 (IH, d),
6.51-6.48 (IH, dd), 6.38-6.36 (IH, d), 6.12-6.10 (IH, dd), 5.97-5.96 (IH, d), 5.53 (2H, s), 4.3 (IH, m), 3.95 (IH, m), 3.56 (IH, m), 3.06 (2H, m), 1.90 ( 2H, m), 1.30 (2H, m).
Example 40
N- f 1 -(4-Cyanobenzoyl)-4-piperidinyl1 -4-chloro-2-pyridinamine The title compound was prepared using the method of Example 3 and starting with 4- chloro-N-(4-piperidinyl)-2-pyradinamine (Intermediate J) and 4-cyanobenzoic acid chloride. The free base was isolated as a white solid. MS(+ Cl) m/z 342/345 ([M + H]+);
400MHz H NMR (d6-DMSO) 7.95-7.92 (3H, m), 7.58 (2H, d), 6.81 (IH, d), 6.54-6.52
(2H, m), 4.38-4.26 (IH, br.m), 4.04-3.95 (IH, br.m), 3.5-3.4 (IH, br.m), 3.2-3.0 (2H, br.m), 2.05-1.8 (2H, br.m), 1.5-1.2 (2H, br.m).
Example 41
4-Cvano-N-f3-r(4-methyl-2-pyridinyl)amino]propynbenzamide
4-Cyanobenzoyl chloride (163 mg, 0.98 mmol) was added to a solution of N'-(4-methyl-2- pyridinyl)-l,3-propanediamine (Intermediate G) (162 mg, 0.98 mmol) and triethylamine (0.5 ml) in dichloromethane (20 ml). After 1 h, the solution was diluted with water, extracted with ethyl acetate, the extract dried over sodium sulphate and evaporated. Purification by column chromatography on silica gel eluting with 3% methanol/dichloromethane gave the title compound as a white solid (130 mg).
MS (+CI) m/z 295 ([M+H]+);
300MHz *H NMR (d6-DMSO) 8.75 (IH, t, J 5.2Hz), 8.00-7.95 (4H, m), 7.80 (IH, d, J
5.2Hz), 6.36 (IH, t, J 5.6Hz), 6.30 (IH, d, J 5.2Hz), 6.25 (IH, s), 3.36-3.24 (4H, m), 2.12 (3H, s), 1.76 (IH, pentet, J 7.2Hz).
Example 42
4-Cyano-N-.3-,(4-methoxy-2-pyridinyl)aminolpropyl]benzamide
The title compound was prepared using the method of Example 42 and starting with
N'-(4-methoxy-2-pyridinyl)-l,3-propanediamine (Intermediate H) as a yellow solid.
MS (+CI) m/z 312 ([M+H]+); 400MHz H NMR (d6-DMSO) 8.76 (IH, t), 8.01-7.94 (4H, apparent dd), 7.76 (IH, d),
6.40 (IH, t), 6.11 (IH, dd), 5.95 (IH, d), 3.70 (IH, t), 6.11 (IH, dd), 5.95 (IH, d), 3.70 (3H, s), 3.37-3.24 (4H, m), 1.76 (2H, pentet).
Example 43
N-ri-(4-Chlorobenzoyl -4-methyl-4-piperidinyll-4-methoxy-2-pyridinamine The title compound was prepared from l-(4-chlorobenzoyl)-4-methyl-4-piperidinamine (Intermediate M) and 2-chloro-4-methoxypyridine using the method of Intermediate A. The hydrochloride salt was obtained as a white solid. MS(+CI) m/z 360/363 ([M+H]+);
400MHz H NMR (d6-DMSO) 8.42 (IH, br.s), 7.97 (IH, d), 7.51 (2H, d), 7.44 (2H, d),
6.57 (IH, d), 6.48 (IH, s), 4.05-4.0 (IH, br.m), 3.93 (3H, s), 3.5-3.3 (3H, m), 2.3-1.8 (2H, m), 1.8-1.7 (2H, br.m), 1.48 (3H, s). Screens
The pharmacological activity of compounds according to the invention was tested in the following screens.
Screen 1
The activity of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, may be screened for nitric oxide synthase inhibiting activity by a procedure based on that of Forstermann et al., Eur. J. Pharm., 1992, 225, 161-165. Nitric oxide synthase converts H-L-arginine into H-L-citrulline which can be separated by cation exchange chromatography and quantified by liquid scintillation counting.
Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from the laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 mg/ml streptomycin & 0.25 mg/ml amphotericin B). Cells are routinely grown in 225 cm3 flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO .
Nitric oxide synthase is produced by cells in response to interferon-g (IFNg) and lipopolysaccharide (LPS). The medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 mg/ml LPS and 10 units/ml IFNg. After a period of 17-20 hours in culture, harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium. Cells are collected by centrifugation (1000 g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1% (v/v) Triton-X-100, 0.1 mM dithiothreitol and a cocktail of protease inhibitors comprising leupeptin (2 mg/ml), soya bean trypsin inhibitor (10 mg/ml), aprotinin (5 mg ml) and phenylmethylsulphonyl fluoride (50 mg/ml).
For the assay, 25 μl of substrate cocktail (50 mM Tris-HCl (pH 7.5 at 20 °C), 400 μM NADPH, 20 μM flavin adenine dinucleotide, 20 μM flavin mononucleotide, 4 μM tetrahydrobiopterin, 12 μM L-arginine and 0.025 mCi L-[3H] arginine) is added to wells of a 96 well filter plate (0.45μM pore size) containing 25 μl of a solution of test compound in 50 mM Tris-HCl. The reaction is started by adding 50 μl of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50 μl of an aqueous solution of 3 mM nitroarginine and 21 mM EDT A.
Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W. 150 μl of a 25% aqueous slurry of Dowex 50W (Na+ form) is added to the assay after which the whole is filtered into 96 well plates. 75 μl of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.
In a typical experiment basal activity is 300 dpm per 75 μl sample which is increased to 1900 dpm in the reagent controls. Compound activity is expressed as IC50 (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and aminoguanidine, which gives an IC50 (50% inhibitory concentration) of 10 μM, is tested as a standard to verify the procedure. Compounds are tested at a range of concentrations and from the inhibitions obtained IC50 values are calculated. Compounds that inhibit the enzyme by at least 25% at 100 μM are classed as being active and are subjected to at least one retest.
In the above screen, the compounds of Examples 1 to 43 were tested and gave IC50 values of less than 25 μM indicating that they are expected to show useful therapeutic activity.
Screen 2
Compounds also show activity against the human form of induced nitric oxide synthase as can be demonstrated in the following assay.
Enzyme is prepared, after induction, from the cultured human colon adrenocarcinoma cell line DLDl (obtained from the European Collection of Animal Cell Culture - cell line number 90102540). DLDl cells are cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin B). Cells are routinely grown in 225 cm3 flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO .
Nitric oxide synthase is produced by cells in response to interferon-γ (IFN-γ) and interleukin-lβ (IL-lβ). The medium from confluent flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 250 units/ml IL-lβ and 1000 units/ml IFN-γ. After a period of 17-20 hours in culture, harvesting of cells is accomplished by scraping the cell monolayer from the flask surface into the culture medium. Cells are collected by centrifugation (lOOOg for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20°C), 10% (v/v) glycerol, 0.1% (v/v) Triton-XlOO, 0.1 mM dithiothreitol and a cocktail of protease inhibitors including leupeptin (2 μg/ml), soya bean trypsin inhibitor (10 μg/ml), aprotonin (5 μg/ml) and phenylmethylsulphonyl fluoride (50 μg/ml).
For the assay, 25 μl of substrate cocktail (50 mM Tris-HCl (pH 7.5), 400 μM NADPH, 20 μM flavin adenine dinucleotide, 20 μM flavin mononucleotide and 4 μM tetrahydrobiopterin) is added to the wells of a 96-well plate. Test compounds are preincubated with enzyme by adding together with 40 μl of cell lysate (prepared as above) and incubating for 1 hour at 37 °C at the end of which period 10 μl of 30 μM L-arginine and 0.025 μCi of L-[3H]-arginine in 50 mM Tris-HCl is added to start the enzymatic reaction. Incubation is continued for a further 1 hour at 37 °C. The reaction is terminated by addition of 50 μl of an aqueous solution of 3 mM nitroarginine and 21 mM EDT A.
Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W. 120 μl of a 25% aqueous slurry of Dowex 50W is added to 96 well filter plates (0.45 μm pore size). To this is added 120 μl of terminated assay mix. 75 μl of filtrate is sampled and added to the wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting. In a typical experiment basal activity is 300 dpm per 75 μl sample of reagent controls, which is increased to 3000 dpm in the presence of enzyme. Compound activity is expressed as IC50 (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and L-NMMA, which gives an IC50 of about 0.4 μM is tested as a standard to verify the procedure. Compounds are tested at a range of concentrations and from the inhibitions obtained IC50 values are calculated.
In this screen the compounds of Examples 1 to 43 gave IC50 values of less than 25 μM, indicating that they are predicted to show useful therapeutic activity.

Claims

CLAIMS:
1. A compound of formula (I)
Figure imgf000042_0001
wherein
6_7, X represents -[CR R ]n-;
R represents hydrogen or one or more substituents selected independently from Cl to 6
8 9 alkyl, Cl to 6 alkoxy, halogen and NR R ;
R ,R ,R ,R ,R ,R ,R and R independently represent hydrogen or Cl to 4 alkyl;
2 4 or R and R are joined together and represent -[CH2]m-;
Y represents hydrogen or Cl to 4 alkyl;
or R and Y are joined together and represent -[CH2]p-;
or R and Y are joined together and represent -[CH2]p-;
or Y is joined to the ortho position of ring A and represents -[CH2]r~; Z represents a bond or -CH2-;
Q represents hydrogen or one or more substituents selected independently from Cl to 6 alkyl, Cl to 6 alkoxy, Cl to 6 alkylthio, halogen, cyano, trifluoromethyl, trifluoromethoxy, hydroxy, nitro, methanesulphonyl, sulphamoyl, benzyloxy, -NR R , -CO2R ,
11 12 -CONR R , a five membered aromatic heterocyclic ring containing one to three heteroatoms independently selected from O, S or N, a six membered aromatic azacyclic ring containing one or two nitrogen atoms, or phenyl, said phenyl being optionally further substituted by Cl to 6 alkyl;
10 1 1 12
R , R and R independently represent hydrogen or Cl to 4 alkyl;
A represents phenyl, naphthyl, a five membered aromatic heterocyclic ring containing one to three heteroatoms independently selected from O, S or N, a six membered aromatic azacyclic ring containing one or two nitrogen atoms, or a bicyclic aromatic heterocyclic ring system containing one to three heteroatoms independently selected from O, S or N;
m represents an integer 0 to 5;
n represents an integer 0 to 3;
p represents an integer 0 to 4;
r represents an integer 0 to 3;
or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
2. A compound of formula (I), according to Claim 1, wherein A represents a phenyl or pyridyl ring.
3. A compound of formula (I), according to Claim 1 or Claim 2, wherein R represents Cl to 6 alkyl or Cl to 6 alkoxy.
4. A compound of formula (I), according to any one of Claims 1 to 3, wherein Q represents hydrogen, halogen or cyano.
5. A compound of formula (I), according to any one of Claims 1 to 4, wherein n represents 0 or 1.
2 6. A compound of formula (I), according to any one of Claims 1 to 5, wherein R and Y in formula (I) are joined together and represent -[CH2]2- and Z represents a bond and n =
2 1, such that R and Y together with the atoms to which they are attached represent a piperidinyl ring.
7. A compound of formula (I) which is:
N-[l-(3-furanylcarbonyl)-4-piperidinyl]-4-methyl-2-pyridinamine;
N-[l-(4-cyanobenzoyl)-4-piperidinyl]-4-methyl-2-pyridinamine;
4-[[3-[(4-methoxy-2-pyridinyl)amino]-l-pyrrolidinyl]carbonyl]benzonitrile;
4-[[4-[(4-methoxy-2-pyridinyl)amino]-l-piperidinyl]carbonyl]benzonitrile; N-[ 1 -(4-bromobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[l-(4-chlorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[ 1 -(2-thienylcarbonyl)-4-piperidinyl]-2-pyridinamine;
N-[l-[(5-chloro-2-thienyl)carbonyl]-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-[[4-[(4-methoxy-2-pyridinyl)amino]-l-piperidinyl]carbonyl]benzenesulphonamide; N-[l-[(6-chloro-3-pyridinyl)carbonyl]-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-(2-pyrazinecarbonyl)-4-piperidinyl]-2-pyridinamine;
N-[ 1 -(3 ,4-dichlorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-(3-thienylcarbonyl)-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[ 1 -(4-methoxybenzoyl)-4-piperidinyl]-2-pyridinamine; N-[ 1 - { (5-bromo-2-thienyl)carbonyl } -4-piperidinyl]-4-methoxy-2-pyridinamine; 4-methoxy-N-[ 1 - { (2-(4-pyridinyl)-4-thiazolyl)carbonyl } -4-piperidinyl]-2-pyridinamine;
N-[l-(3,5-dibromobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[l-(4-chloro-3-iodobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[l-(3-isoqunolinylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine; 4-methoxy-N-[l-(6-quinolinylcarbonyl)-4-piperidinyl]-2-pyridinamine;
N-[l-(3,5-difluorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[ 1 -[(5-methyl- 1 -phenyl- l /-pyrazol-4-yl)carbonyl]-4-piperidinyl]-2- pyridinamine;
N-[l-[4-(dimethylamino)benzoyl]-4-piperidinyl]-4-methoxy-2-pyridinamine; 4-methoxy-N-[ 1 -(3-quinolinylcarbonyl)-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-[(6-methyl-3-pyridinyl)carbonyl]-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-[4-(lH-pyrrol-l-yl)benzoyl]-4-piperidinyl]-2-pyridinamine;
N-[ 1 -(4-iodobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[ 1 -( 1 -benzothiophen-2-ylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine; N- [ 1 - [(4'-ethyl [1,1 '-biphenyl] -4-y l)carbonyl] -4-piperidinyl] -4-methoxy-2-pyridinamine ;
N-[ 1 -( \H- 1 ,2,3-benzotriazol-5-ylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[ 1 -[4-( 1 -methylethyl)benzoyl]-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-(l,2,3-thiadiazol-4-ylcarbonyl)-4-piperidinyl]-2-pyridinamine;
4-methoxy-N-[l-(3-pyridinylcarbonyl)-4-piperidinyl]-2-pyridinamine; 4-methoxy-N-[l-(2-pyridinylcarbonyl)-4-piperidinyl]-2-pyridinamine;
N-[l-(3-isoxazolylcarbonyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-[(5-methyl-2-pyrazinyl)carbonyl]-4-piperidinyl]-2-pyridinamine;
N-[l-[4-(aminomethyl)benzoyl]-4-piperidinyl]-4-methoxy-2-pyridinamine;
4-methoxy-N-[l-(4-pyridinylcarbonyl)-4-piperidinyl]-2-pyridinamine; N-[ 1 -(3-amino-4-chlorobenzoyl)-4-piperidinyl]-4-methoxy-2-pyridinamine;
N-[ 1 -(4-cyanobenzoyl)-4-piperidinyl]-4-chloro-2-pyridinamine;
4-cyano-N-[3-[(4-methyl-2-pyridinyl)amino]propyl]benzamide;
4-cyano-N-[3-[(4-methoxy-2-pyridinyl)amino]propyl]benzamide;
N-[l-(4-chlorobenzoyl)-4-methyl-4-piperidinyl]-4-methoxy-2-pyridinamine; or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.
8. A compound of formula (I), according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, for use as a medicament.
9. A pharmaceutical composition comprising a compound of formula (I) according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
10. The use of a compound of formula (I) according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.
11. The use as claimed in Claim 10 wherein it is predominantly inducible nitric oxide synthase that is inhibited.
12. The use of a compound of formula (I) as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.
13. The use as claimed in Claim 12 wherein the disease is inflammatory bowel disease.
14. The use as claimed in Claim 12 wherein the disease is rheumatoid arthritis.
15. The use as claimed in Claim 12 wherein the disease is osteoarthritis.
16. The use of a compound of formula (I) as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, in the manufacture of a medicament, for the treatment or prophylaxis of pain.
17. The use of a compound of formula (I) as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, in combination with a COX-2 inhibitor, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.
18. A method of treating, or reducing the risk of, human diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, to a person suffering from, or at increased risk of, such diseases or conditions.
19. A method of treatment according to Claim 18 in which it is predominantly inducible nitric oxide synthase that is inhibited.
20. A method of treating, or reducing the risk of, inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.
21. The method of treatment as claimed in Claim 20 wherein the disease is inflammatory bowel disease.
22. The method of treatment as claimed in Claim 20 wherein the disease is rheumatoid arthritis.
23. The method of treatment as claimed in Claim 20 wherein the disease is osteoarthritis.
24. A method of treating, or reducing the risk of, pain in a person suffering from, or at risk of, said condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.
25. A method of treating, or reducing the risk of, inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a combination of a compound of formula (I), as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, with a COX-2 inhibitor.
26. A process for the preparation of a compound of formula (I), as defined in any one of Claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, wherein the process comprises:
(a) preparing a compound of formula (I) by reaction of a compound of formula (H)
Figure imgf000048_0001
wherein
1 2 3 4 5 R , R , R , R , R , X, Y and Z are as defined in Claim 1 with an acyl derivative of formula (HI)
Figure imgf000048_0002
wherein
Q and A are as defined in Claim 1 and L represents a leaving group; or (b) preparing a compound of formula (I) by reaction of a compound of formula (IV)
Figure imgf000049_0001
.1 . wherein R is as defined in Claim 1 with a compound of formula (V)
Figure imgf000049_0002
2 4 5 wherein R , R , R ' A, Q, X, Y and Z are as defined in Claim 1 ;
or (c) preparing a compound of formula (I) by reaction of a compound of formula (VT)
Figure imgf000049_0003
.1 wherein R is as defined in Claim 1, with a compound of formula (VH)
Figure imgf000049_0004
2 3 4 5 wherein R , R , R , R , A, Q, X, Y and Z are as defined in Claim 1 ; and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof, or vice versa, and where desired converting the resultant compound of formula (I) into an optical isomer thereof.
PCT/SE1999/001988 1998-11-05 1999-11-03 Compounds Ceased WO2000027842A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU14345/00A AU1434500A (en) 1998-11-05 1999-11-03 Compounds
JP2000581020A JP2002529463A (en) 1998-11-05 1999-11-03 Compound
EP99971807A EP1124821A1 (en) 1998-11-05 1999-11-03 Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803773-2 1998-11-05
SE9803773A SE9803773D0 (en) 1998-11-05 1998-11-05 Compounds

Publications (1)

Publication Number Publication Date
WO2000027842A1 true WO2000027842A1 (en) 2000-05-18

Family

ID=20413181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/001988 Ceased WO2000027842A1 (en) 1998-11-05 1999-11-03 Compounds

Country Status (5)

Country Link
EP (1) EP1124821A1 (en)
JP (1) JP2002529463A (en)
AU (1) AU1434500A (en)
SE (1) SE9803773D0 (en)
WO (1) WO2000027842A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002387A1 (en) * 1999-07-05 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. N-imidazolylmethyl carboxamides as nitric oxide production inhibitors
US6887871B2 (en) 2000-02-23 2005-05-03 Astrazeneca Ab Use of phenylheteroakylamine derivatives
US6900243B2 (en) 2000-02-23 2005-05-31 Astrazeneca Ab Phenylheteroalkylamine derivatives
US6953797B2 (en) 2000-02-23 2005-10-11 Astrazeneca Ab Use of phenylheteroalkylamine derivatives
EP1627869A4 (en) * 2003-05-20 2006-10-18 Ajinomoto Kk Amide derivative
US7223794B2 (en) 2001-07-31 2007-05-29 Astrazeneca Ab Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
CN100340548C (en) * 2001-05-08 2007-10-03 阿斯利康(瑞典)有限公司 Novel arylheteroalkylamine derivatives
US7776861B2 (en) 2003-07-24 2010-08-17 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7897627B2 (en) * 2007-12-21 2011-03-01 Hoffmann-La Roche Inc. Heteroaryl derivatives as orexin receptor antagonists
US7923450B2 (en) 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
US8288403B2 (en) 2008-11-10 2012-10-16 Hoffmann-La Roche Inc. Heterocyclic gamma secretase modulators
US8389717B2 (en) 2008-10-09 2013-03-05 Hoffmann-La Roche Inc. Modulators for amyloid beta
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8962834B2 (en) 2008-02-22 2015-02-24 Hoffmann-La Roche Inc. Modulators of amyloid beta

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018628A1 (en) * 1994-12-13 1996-06-20 Pharmacia & Upjohn Company Alkyl substituted piperadinyl and piperazinyl anti-aids compounds
WO1996018617A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997037655A1 (en) * 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS
EP0870765A1 (en) * 1995-05-18 1998-10-14 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018617A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1996018628A1 (en) * 1994-12-13 1996-06-20 Pharmacia & Upjohn Company Alkyl substituted piperadinyl and piperazinyl anti-aids compounds
EP0870765A1 (en) * 1995-05-18 1998-10-14 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997037655A1 (en) * 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002387A1 (en) * 1999-07-05 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. N-imidazolylmethyl carboxamides as nitric oxide production inhibitors
US6887871B2 (en) 2000-02-23 2005-05-03 Astrazeneca Ab Use of phenylheteroakylamine derivatives
US6900243B2 (en) 2000-02-23 2005-05-31 Astrazeneca Ab Phenylheteroalkylamine derivatives
US6953797B2 (en) 2000-02-23 2005-10-11 Astrazeneca Ab Use of phenylheteroalkylamine derivatives
CN100340548C (en) * 2001-05-08 2007-10-03 阿斯利康(瑞典)有限公司 Novel arylheteroalkylamine derivatives
WO2002090332A3 (en) * 2001-05-08 2007-11-01 Astrazeneca Ab Novel aeylheteroalkylaminε derivatives
AU2002306039B2 (en) * 2001-05-08 2008-05-29 Astrazeneca Ab Novel arylheteroalkylamine derivatives
US7223794B2 (en) 2001-07-31 2007-05-29 Astrazeneca Ab Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
US8168827B2 (en) 2003-05-20 2012-05-01 Ajinomoto Co., Inc. Amide derivative
EP1627869A4 (en) * 2003-05-20 2006-10-18 Ajinomoto Kk Amide derivative
US7572815B2 (en) 2003-05-20 2009-08-11 Ajinomoto Co., Inc. Amide derivative
US7776861B2 (en) 2003-07-24 2010-08-17 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8178560B2 (en) 2003-07-24 2012-05-15 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8637548B2 (en) 2003-07-24 2014-01-28 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US9301953B2 (en) 2003-07-24 2016-04-05 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7897627B2 (en) * 2007-12-21 2011-03-01 Hoffmann-La Roche Inc. Heteroaryl derivatives as orexin receptor antagonists
US7923450B2 (en) 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
US8962834B2 (en) 2008-02-22 2015-02-24 Hoffmann-La Roche Inc. Modulators of amyloid beta
US8389717B2 (en) 2008-10-09 2013-03-05 Hoffmann-La Roche Inc. Modulators for amyloid beta
US8288403B2 (en) 2008-11-10 2012-10-16 Hoffmann-La Roche Inc. Heterocyclic gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines

Also Published As

Publication number Publication date
EP1124821A1 (en) 2001-08-22
AU1434500A (en) 2000-05-29
SE9803773D0 (en) 1998-11-05
JP2002529463A (en) 2002-09-10

Similar Documents

Publication Publication Date Title
DE60029235T2 (en) FAB I INHIBITORS
US20250376473A1 (en) Prmts inhibitor and use thereof
EP2751108B1 (en) Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US10155756B2 (en) Pyrazolo[1,5-A]pyridine compounds and use thereof
AU2016372028B2 (en) Methods of treating hyperalgesia
EP2734516B1 (en) Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
WO2000021934A1 (en) Compounds
AU2003251272A1 (en) Use of and some novel imidazopyridines
KR20120063283A (en) Novel pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
EP1124821A1 (en) Compounds
CA2470427C (en) Compositions and methods for treating heart failure
JP5487100B2 (en) Triazolo [1,5-A] quinoline as adenosine A3 receptor ligand
EP2411368A1 (en) Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
KR102816191B1 (en) Novel heterocyclic histone deacetylase inhibitors and pharmaceutical composition comprising the same
CN106316975A (en) Amide compound and application thereof as TGR5 agonist
JP6353899B2 (en) Inhibitors of leukotriene production
CN114901642B (en) A fused ring compound and its application
CA3103351A1 (en) Pqsr inverse agonists
CN116981665A (en) new compounds
CN102532009B (en) A compound for inhibiting dipeptide kininase and its preparation method and use
US9573957B2 (en) Inhibitors of leukotriene production
EP4171569A1 (en) Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof
WO2010059555A1 (en) Prolyl hydroxylase inhibitors
KR20260012673A (en) 4'-Phosphopantetheinyl transferase enzyme inhibitors and Pharmaceutical composition for use in preventing or treating tuberculosis containing the same as an active ingredient
EP1539731B9 (en) Novel compounds

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 14345

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09486659

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999971807

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581020

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999971807

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999971807

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642